Premium
AT1R blockade together with AT2R stimulation prevents aortic aneurysm in mice with progressively severe Marfan syndrome
Author(s) -
Asano Keiichi,
Cantalupo Anna,
Hansen Jens,
Spronck Bart,
Humphrey Jay D.,
Iyengar Ravi,
Ramirez Francesco
Publication year - 2022
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2022.36.s1.r5562
Subject(s) - losartan , medicine , angiotensin ii , marfan syndrome , aortic aneurysm , thoracic aortic aneurysm , aorta , vasodilation , cardiology , receptor
Angiotensin II receptor signaling regulate vascular tone by stimulating either vasoconstriction (AT1R) or vasodilation (AT2R). AT1R antagonism (via losartan) has been shown to mitigate thoracic aortic aneurysm (TAA) progression in mouse models of Marfan syndrome (MFS). Here we monitored multiple pathological readouts of TAA in MFS mice chronically treated for 90 days with either losartan, the AT2R agonist C21, or both. While C21 had no apparent effects on arterial disease by itself, it significantly enhanced losartan’s efficacy by preventing death of MFS mice from ruptured TAA during the treatment period. Specifically, the combination therapy normalized the diameters of the aortic root and ascending aorta, the architecture of the vessel wall, endothelial‐dependent relaxation, and circumferential wall strength (a strong biomechanical indicator of aneurysmal vulnerability). Computational analyses of bulk RNASeq data predicted that the combination therapy largely decreased expression of abnormally upregulated genes, principally those associated with inflammatory pathways. By contrast, these in silico analyses predicted no modifications of signaling pathways associated with dysregulated mitochondrial energy metabolism. Ongoing investigations are using single cell RNASeq to identify the different cell types targeted by the two drugs used in combination therapy, as well as potential cell‐cell interactions that underlie the efficacy of the combination therapy.